These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 27085220)

  • 21. A multicenter post-marketing evaluation of the Elixir DESolve
    Nef H; Wiebe J; Boeder N; Dörr O; Bauer T; Hauptmann KE; Latib A; Colombo A; Fischer D; Rudolph T; Foin N; Richardt G; Hamm C
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):1021-1027. PubMed ID: 29508518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study.
    Abizaid A; Carrié D; Frey N; Lutz M; Weber-Albers J; Dudek D; Chevalier B; Weng SC; Costa RA; Anderson J; Stone GW;
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1832-1838. PubMed ID: 28935075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-year outcomes after deployment of XIENCE V everolimus-eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: a report from the SPIRIT V single arm study.
    Džavík V; Kaul U; Guagliumi G; Chevalier B; Smits PC; Stuteville M; Li D; Sudhir K; Grube E
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E163-72. PubMed ID: 23225766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial.
    Costa JR; Abizaid A; Whitbourn R; Serruys PW; Jepson N; Steinwender C; Stuteville M; Ediebah D; Sudhir K; Bartorelli AL;
    Catheter Cardiovasc Interv; 2019 Jan; 93(1):E1-E7. PubMed ID: 30286520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
    Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
    EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
    Xu K; Fu G; Xu B; Zhou Y; Su X; Liu H; Zhang Z; Yu B; Wang X; Han Y;
    Catheter Cardiovasc Interv; 2019 Feb; 93(S1):832-838. PubMed ID: 30888736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Very Late Scaffold Thrombosis after Everolimus-Eluting Bioresorbable Scaffold Implantation in Patients with Unremarkable Interim Surveillance Angiography.
    Hoppmann P; Rai H; Colleran R; Kufner S; Wiebe J; Cassese S; Joner M; Laugwitz KL; Kastrati A; Byrne RA
    Cardiovasc Revasc Med; 2020 Mar; 21(3):361-366. PubMed ID: 31231028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent　- A Randomized Comparison Through 5 Years in Japan.
    Kozuma K; Tanabe K; Hamazaki Y; Okamura T; Ando J; Ikari Y; Nakagawa Y; Kusano H; Ediebah D; Kimura T;
    Circ J; 2020 Apr; 84(5):733-741. PubMed ID: 32213737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Procedural resources utilization and clinical outcomes with bioresorbable everolimus-eluting scaffolds and Pt-Cr everolimus-eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial.
    de la Torre Hernandez JM; Garcia Camarero T; Lee DH; Sainz Laso F; Veiga Fernandez G; Pino T; Rubio S; Legarra P; Valdivia JR; Zueco Gil J
    Catheter Cardiovasc Interv; 2017 Aug; 90(2):E25-E30. PubMed ID: 27807948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial.
    van Houwelingen KG; van der Heijden LC; Lam MK; Kok MM; Löwik MM; Louwerenburg JW; Linssen GC; IJzerman MJ; Doggen CJ; von Birgelen C
    Heart Vessels; 2016 Nov; 31(11):1731-1739. PubMed ID: 26747438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: Four-year results from the Xience V USA study.
    Hermiller JB; Applegate RJ; Baird C; Butler MM; Rutledge D; Wang J; Kakarala K; Krucoff MW; Sudhir K
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):62-70. PubMed ID: 26399687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY-IT study.
    Ielasi A; Varricchio A; Campo G; Leoncini M; Cortese B; Vicinelli P; Brugaletta S; di Uccio FS; Latib A; Tespili M
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1129-1138. PubMed ID: 27774758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions).
    Kandzari DE; Kini AS; Karmpaliotis D; Moses JW; Tummala PE; Grantham JA; Orr C; Lombardi W; Nicholson WJ; Lembo NJ; Popma JJ; Wang J; Larracas C; Rutledge DR
    JACC Cardiovasc Interv; 2015 May; 8(6):761-769. PubMed ID: 25912400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
    Kervinen K; Niemelä M; Romppanen H; Erglis A; Kumsars I; Maeng M; Holm NR; Lassen JF; Gunnes P; Stavnes S; Jensen JS; Galløe A; Narbute I; Sondore D; Christiansen EH; Ravkilde J; Steigen TK; Mannsverk J; Thayssen P; Hansen KN; Helqvist S; Vikman S; Wiseth R; Aarøe J; Jokelainen J; Thuesen L;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1160-5. PubMed ID: 24262616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions).
    Azzalini L; Giustino G; Ojeda S; Serra A; La Manna A; Ly HQ; Bellini B; Benincasa S; Chavarría J; Gheorghe LL; Longo G; Miccichè E; D'Agosta G; Picard F; Pan M; Tamburino C; Latib A; Carlino M; Chieffo A; Colombo A
    Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27765802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.